Havana, Feb 15 (Prensa Latina) The protocol of care for Covid-19 patients in Cuba today focuses its gaze on high-risk patients, those who can go to serious stages due to their associated pathologies.
The most up-to-date version of the protocol, version 1.6, is already available for health personnel and emphasizes preventive work, in tune with the current epidemiological situation, when the number of patients is around 850 daily cases and so far in February there are registered 10 thousand 697 new infections and 50 deaths.
The use of immunomodulators developed in the country such as Biomodulin T and recombinant human interferon alpha 2b constitute a constant from the first moments of confrontation with the disease.
The main modification now is to treat patients classified as high risk with enough time and to do it in a differentiated way through intensive surveillance. For example, suspects who test positive for antigen immediately begin receiving Interferon. ‘One hour is important, 10 much more and 24 very important. You have to win in time, ” explained Ileana Morales, national director of Science and Technological Innovation of the Cuban Ministry of Public Health, in a recent speech.
Of this group, those with low risk receive intensive surveillance and treatment and those with high risk are transferred to hospitals to receive the established protocol.
The other change regarding suspects is that those with high risk, if they present any symptoms that suggest inflammation, receive Interferon in the same way and, in addition, Itolizumbab or Jusvinza, the latter with encouraging results in seriously ill and critically ill .
Due to their comorbidities and possible greater transition to severity, these patients constitute a decisive group to decouple the incidence of mortality, for which they will also receive Heberferon / Heberon (interferons) in their care.
The changes include renewing clinical treatments for the confirmed and asymptomatic patient category, the latter will be included in a controlled trial for the replacement of Heberon by Nasalferon, that is, the injectable version of recombinant human interferon alpha 2 B through the nasal.
The health authorities explain that the protocol is always subject to change and its main premise is that the population does not get sick, and if it is infected, it does not worsen, much less die.
Source: Prensa Latina
Views: 0
